EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Point‐of‐Care Biomarker Monitoring of Treatment Efficacy: Changes in Mouthrinse Active Matrix Metalloproteinase‐8 (aMMP‐8) Concentrations Following Periodontal Anti‐Infective Treatment

Louis R Gieselmann iD, Juulia Rintamarttunen, Mutlu Keskin iD, Ismo T Räisänen iD, Taina Tervahartiala iD, Tommi Pätilä iD, Dirk Neefs iD, Andreas Pfützner iD, Timo Sorsa

International Journal of Dentistry · 2026-01 · 2026 (1)

DOI: 10.1155/ijod/4285673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dentistry, online erschienen am 24.02.2026. Verfasst von Louis R Gieselmann und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Education and Psychology, Free University of Berlin, Berlin, Germany, fu-berlin.de. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karolinska Institutet, Helsingin Yliopisto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The active matrix metalloproteinase‐8 (aMMP‐8) is a functional biomarker of active periodontal tissue destruction. It bridges the gap between clinical findings and underlying biological processes, providing information on active collagen degradation that conventional clinical examinations do not capture.

Methods

In a prospective within‐subject clinical study, we assessed point‐of‐care (PoC) mouthrinse aMMP‐8 concentrations, periodontal probing depth (PPD), and clinical attachment level (CAL) in 27 adults with stage III/IV (grade C) periodontitis before and 1 month after anti‐infective treatment. aMMP‐8 PoC results were validated by laboratory western blotting using an independent polyclonal MMP‐8 antibody.

Results

At baseline, 85.2% of samples showed elevated aMMP‐8 PoC concentrations, declining to 18.5% post‐treatment. Baseline aMMP‐8 was significantly associated with disease severity, correlating with both PPD ( r s = 0.39, p = 0.045) and CAL ( r s = 0.39, p = 0.042). Following treatment, aMMP‐8 concentrations decreased significantly ( V = 378, p < 0.001), with mean reductions of 78.5 ± 72.6 ng/mL ( d = –1.08). Biochemical reductions paralleled clinical improvements, with 100% directional concordance between changes in aMMP‐8 and changes in PPD and CAL (95% CI 0.87–1.00). Reductions in aMMP‐8 were correlated with improvements in PPD ( r s = 0.47, p = 0.014) but not CAL ( r s = 0.12, p = 0.544). Linear regression analysis indicated that each 10 ng/mL reduction in aMMP‐8 corresponded to an estimated 0.034 mm gain in PPD.

Conclusion

These findings demonstrate that aMMP‐8 PoC monitoring aligns with both baseline disease severity and short‐term periodontal healing. aMMP‐8 provides an objective biochemical dimension to periodontal assessment, capturing active collagen degradation and serving as a sensitive and clinically meaningful indicator of treatment response.

Schlagwörter

Stichwörter der Autor:innen

aMMP-8chairside testdiagnostic accuracymatrix metalloproteinase-8 (MMP-8)mouthrinse sampleperiodontal diagnosisperiodontal treatmentperiodontitispoint-of-care testingtreatment monitoring

Autor:innen und Institutionen

  • Department of Education and Psychology, Free University of Berlin, Berlin, Germany, fu-berlin.de.
  • Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland, helsinki.fi.
  • Department of Periodontology, University of Kyrenia, Kyrenia, Cyprus, kyrenia.edu.tr.
  • Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, helsinki.fi.
  • Department of Pediatric Surgery, New Children's Hospital, University of Helsinki, Helsinki, Finland, helsinki.fi.
  • Department of Biomedical, Surgical, and Dental Science, Universitá degli Studii di Milano, Milan, Italy, unimib.it.

ORCID-Profile: Louis R Gieselmann, Mutlu Keskin, Ismo T Räisänen, Taina Tervahartiala, Tommi Pätilä, Dirk Neefs, Andreas Pfützner

Förderung

  • Karolinska Institutet
  • Helsingin Yliopisto

Zitieren

APA

Gieselmann, L. R., Rintamarttunen, J., Keskin, M., Räisänen, I. T., Tervahartiala, T., Pätilä, T., Neefs, D., Pfützner, A., & Sorsa, T. (2026). Point‐of‐Care Biomarker Monitoring of Treatment Efficacy: Changes in Mouthrinse Active Matrix Metalloproteinase‐8 (aMMP‐8) Concentrations Following Periodontal Anti‐Infective Treatment. International Journal of Dentistry, 2026(1). https://doi.org/10.1155/ijod/4285673

Vancouver

Gieselmann LR, Rintamarttunen J, Keskin M, Räisänen IT, Tervahartiala T, Pätilä T, et al. Point‐of‐Care Biomarker Monitoring of Treatment Efficacy: Changes in Mouthrinse Active Matrix Metalloproteinase‐8 (aMMP‐8) Concentrations Following Periodontal Anti‐Infective Treatment. International Journal of Dentistry. 2026;2026(1). doi:10.1155/ijod/4285673

BibTeX
@article{Gieselmann2026,
  author = {Gieselmann, Louis R and Rintamarttunen, Juulia and Keskin, Mutlu and Räisänen, Ismo T and Tervahartiala, Taina and Pätilä, Tommi and Neefs, Dirk and Pfützner, Andreas and Sorsa, Timo},
  title = {Point‐of‐Care Biomarker Monitoring of Treatment Efficacy: Changes in Mouthrinse Active Matrix Metalloproteinase‐8 (aMMP‐8) Concentrations Following Periodontal Anti‐Infective Treatment},
  journal = {International Journal of Dentistry},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ijod/4285673}
}
Kostenlos starten →